| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Product revenues, net | 12,001,300 | 11,020,100 | 9,869,200 | 8,930,700 |
| Cost of sales | 1,651,300 | 1,530,500 | 1,262,200 | 1,080,300 |
| Research and development expenses | 3,909,500 | 3,630,300 | 3,162,900 | 2,540,300 |
| Acquired in-process research and development expenses | 133,000 | 4,628,400 | 527,100 | 115,500 |
| Selling, general and administrative expenses | 1,753,100 | 1,464,300 | 1,136,600 | 944,700 |
| Intangible asset impairment charge | 379,000 | NaN | NaN | NaN |
| Change in fair value of contingent consideration | 2,100 | -500 | -51,600 | -57,500 |
| Total costs and expenses | 7,828,000 | 11,253,000 | 6,037,200 | 4,623,300 |
| Income (loss) from operations | 4,173,300 | -232,900 | 3,832,000 | 4,307,400 |
| Interest income | 490,900 | 598,100 | 614,700 | 144,600 |
| Interest expense | 13,300 | 30,600 | -44,100 | -54,800 |
| Other expense, net | -7,700 | -86,100 | -22,800 | -164,800 |
| Income before provision for income taxes | 4,643,200 | 248,500 | 4,379,800 | 4,232,400 |
| Provision for income taxes | 690,000 | 784,100 | 760,200 | 910,400 |
| Income (loss) | 3,953,200 | -535,600 | 3,619,600 | 3,322,000 |
| Basic EPS | 15.46 | -2.08 | 14.05 | 12.97 |
| Diluted EPS | 15.32 | -2.08 | 13.89 | 12.82 |
| Basic Average Shares | 255,700,000 | 257,900,000 | 257,700,000 | 256,100,000 |
| Diluted Average Shares | 258,000,000 | 257,900,000 | 260,500,000 | 259,100,000 |
VERTEX PHARMACEUTICALS INC MA (VRTX)
VERTEX PHARMACEUTICALS INC MA (VRTX)